Plasma Exchange for Immune Checkpoint Inhibitor–Induced Myocarditis
Haran Yogasundaram, Waleed Alhumaid, June W. Chen, Matthew Church, Naji Alhulaimi, Shane Kimber, D. Ian Paterson, Janek Senaratne
Abstract
Immune checkpoint inhibitor therapy has been shown to improve outcomes across many types of malignancies. However, immune checkpoint inhibitor has been associated with several immune-related adverse events including myocarditis. We describe the case of a 69-year-old man with fulminant myocarditis likely due to pembrolizumab therapy, complicated by biventricular failure with cardiogenic shock. Because of deterioration in hemodynamic status refractory to conventional immunosuppression, therapeutic plasma exchange was performed, resulting in a rapid reduction of serum pembrolizumab levels, and marked clinical, radiological, and biochemical improvement. To our knowledge, this is the first reported case on the successful use of plasma exchange for pembrolizumab-associated fulminant myocarditis.